Peng Mei, Xiao Di, Bu Yizhi, Long Jiahui, Yang Xue, Lv Shuhe, Yang Xiaoping
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, China.
Front Oncol. 2021 Jan 27;10:539527. doi: 10.3389/fonc.2020.539527. eCollection 2020.
Bladder cancer is the ninth most frequently diagnosed cancer world-wide and ranks 13th in cancer-related deaths. Two tremendous breakthroughs in bladder cancer therapy over the last decades are the approval of immune checkpoint inhibitors(ICIs)and the fibroblast growth factor receptor tyrosine kinase inhibitor (FGFR-TKI) erdafitinib for treating this deadly disease. Despite the beneficial effects of these approaches, the low response rate and the potential resistance of the cancer are major concerns. Hence, novel combination therapies to overcome these limitations have been investigated. In this context, combining immunotherapy with targeted drugs is an appealing therapeutic option to improve response and reduce the emergence of resistance in the management of bladder cancer. In this review, the rationale of using different therapeutic combinations is discussed according to the mechanistic differences, emphasizing the efficacy and safety based on evidence collected from preclinical and clinical studies. Finally, we highlight the limitations of these combinations and provide suggestions for further efforts in this challenging field.
膀胱癌是全球第九大最常被诊断出的癌症，在癌症相关死亡中排名第13位。在过去几十年里，膀胱癌治疗领域的两大重大突破是免疫检查点抑制剂（ICIs）的获批以及用于治疗这种致命疾病的成纤维细胞生长因子受体酪氨酸激酶抑制剂（FGFR-TKI）厄达替尼。尽管这些方法有有益效果，但癌症的低反应率和潜在耐药性仍是主要问题。因此，人们一直在研究克服这些局限性的新型联合疗法。在此背景下，将免疫疗法与靶向药物联合使用是改善膀胱癌治疗反应和减少耐药性出现的一种有吸引力的治疗选择。在这篇综述中，根据作用机制的差异讨论了使用不同治疗组合的基本原理，并基于临床前和临床研究收集的证据强调了疗效和安全性。最后，我们强调了这些组合的局限性，并为在这个具有挑战性的领域进一步开展研究提供了建议。
